A one-stop platform promoting a highly cooperative and mutually beneficial bio-pharmaceutical ecosystem in SEA

As an emerging economy with promising potential, the Southeast Asian market has a relatively rapid economic development, considerable demographic dividend, sound business atmosphere, and a series of favorable policies supporting the industry, thus the development of its healthcare industry has shown vigorous vitality. Within 30 years of global investment and acquisition experience, proven commercialization capabilities, and deep insight into business opportunities, the Group’s Southeast Asia(SEA) business，“Rxilient Health” is building a professional and experienced local core management team in SEA that can quickly take root in the local market. Relying on first-mover advantages, Rxilient Health is gradually building a systematic and platform-based operation structure that covers “product introduction，developing, manufacturing, preparation CDMO, marketing and promotion”, striving to becoming a “bridgehead” to enter the SEA market for global pharmaceutical companies.

Main Marketed Products

EyeOP1 Glaucoma Treatment Device (exclusive product)

Indication
Glaucoma with intraocular pressure that cannot be controlled by drugs and surgery

 

Combizym (Oryz-aspergillus Enzyme and Pancreatin Tablets) (exclusive product)

Indication
Dyspepsia caused by a decrease in digestive enzymes

The information on this page is only for the introduction of the medicines and medical devices to partners or medical professionals, not for product advertising. The product information on this website shall not replace medical advice and medical consultation provided by doctors or other qualified medical professionals, and shall not be used for disease diagnosis. For detailed information about the medicines and medical devices, please refer to the latest product instructions. If you have understood and confirmed the above content, please click OK to enter.